Autocrine motility factor/glucose‐6‐phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours
- 17 November 2005
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 208 (1) , 44-53
- https://doi.org/10.1002/path.1878
Abstract
In order to assess the involvement of autocrine motility factor (AMF) in mesenchymal tumours, AMF protein and mRNA expression was analysed in tumours, tumour‐like lesions, and other lesions of bone and soft tissue. Immunohistochemical analysis of 200 cases revealed positive staining in 72.5% of the cases, suggesting that AMF is a widely expressed protein. Chordoid, chondroid, and muscular tumours revealed higher immunoreactivity in both benign and malignant tumours. Immunoblotting analysis corroborated the results of immunohistochemistry. Generally, malignant tumours revealed higher expression of AMF than benign tumours of the same histopathological lineage, except for dermatofibroma/dermatofibrosarcoma protuberans. However, mRNA levels were not concordant with protein levels, and sarcomas that displayed higher mRNA and lower protein expression levels showed a trend for distant metastasis. In cultured cells, AMF was secreted and detected in conditioned culture medium. Furthermore, when proteasome inhibitors were added to cells in order to examine the changes in turnover rates, these compounds did not significantly alter the intracellular levels of AMF protein. On the basis of these overall findings, it is suggested that a particular subset of sarcomas secrete AMF, rather than degrading this protein at a higher turnover rate. This secreted AMF presumably enhances their cell motility through an autocrine effect and eventually causes increased metastatic potential. Collectively, AMF was observed in a wide spectrum of lesions of mesenchymal tissue, supporting the notion that it is involved in various cellular functions, including proliferation, differentiation, metabolism, and metastasis. In addition, higher expression of its mRNA may indicate higher levels of protein secretion and define a particularly aggressive group of tumours with high metastatic potential. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Both Sp1 and Smad participate in mediating TGF-β1-induced HGF receptor expression in renal epithelial cellsAmerican Journal of Physiology-Renal Physiology, 2005
- Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf‐1 and Caspase‐9 apoptosome expressionInternational Journal of Cancer, 2003
- Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomasThe Journal of Pathology, 2002
- Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt‐1) expression in endothelial cellsInternational Journal of Cancer, 2002
- Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian sarcoma group phase II studyEuropean Journal Of Cancer, 1997
- Constitutive Overexpression of CDK2 Inhibits Neuronal Differentiation of Rat Pheochromocytoma PC12 CellsPublished by Elsevier ,1995
- Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcomaClinical & Experimental Metastasis, 1994
- Autocrine Motility Factor Is a Growth FactorBiochemical and Biophysical Research Communications, 1993
- The Diagnostic Validity of the Serum Tumor Marker Phosphohexose Isomerase (PHI) in Patients with Gastrointestinal, Kidney, and Breast CancerCancer Investigation, 1990
- Detection of Autocrine Motility Factor in Urine as a Marker of Bladder CancerJNCI Journal of the National Cancer Institute, 1988